Article info
PDFClinical and epidemiological research
Concise report
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
- Correspondence to Professor Stanley B Cohen, Metroplex Clinical Research Center, Dallas, TX 75231, USA; Scohen{at}arthdocs.com
Citation
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
Publication history
- Received August 17, 2017
- Revised January 31, 2018
- Accepted February 7, 2018
- First published March 7, 2018.
Online issue publication
August 02, 2020
Article Versions
- Previous version (2 May 2019).
- Previous version (2 May 2019).
- Previous version (2 May 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/